Drug
mirabegron 25 mg
mirabegron 25 mg is a pharmaceutical drug with 5 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
67%(2 trials)
Phase Distribution
Ph phase_2
1
20%
Ph phase_3
3
60%
Ph phase_4
1
20%
Phase Distribution
0
Early Stage
1
Mid Stage
4
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)
Phase 4Post-market surveillance
1(20.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
5
all time
Status Distribution
Active(2)
Completed(3)
Detailed Status
Completed3
Active, not recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (20.0%)
Phase 33 (60.0%)
Phase 41 (20.0%)
Trials by Status
completed360%
active_not_recruiting120%
recruiting120%
Recent Activity
2 active trials
Showing 5 of 5
completedphase_4
A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients
NCT07533565
completedphase_2
Using Mirabegron to Increase BP in Patients With POTS
NCT06133075
active_not_recruitingphase_3
Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children
NCT07398261
recruitingphase_3
Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms
NCT06803030
completedphase_3
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
NCT01908829
Clinical Trials (5)
Showing 5 of 5 trials
NCT07533565Phase 4
A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients
NCT06133075Phase 2
Using Mirabegron to Increase BP in Patients With POTS
NCT07398261Phase 3
Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children
NCT06803030Phase 3
Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms
NCT01908829Phase 3
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5